Literature DB >> 6133894

Combination therapy by using cyclophosphamide and tumor-sensitized lymphocytes: a possible mechanism of action.

R Evans.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6133894

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.422


× No keyword cloud information.
  8 in total

1.  Cancer chemotherapeutics as immunomodulators.

Authors:  F Spreafico; A Vecchi; F Colotta; A Montovani
Journal:  Springer Semin Immunopathol       Date:  1985

2.  Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.

Authors:  E Proietti; G Greco; B Garrone; S Baccarini; C Mauri; M Venditti; D Carlei; F Belardelli
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

3.  Specific adoptive immunotherapy of malignant glioma with long-term cytotoxic T lymphocyte line expanded in T-cell growth factor. Experimental study and future prospects.

Authors:  T Yamasaki; H Handa; J Yamashita; Y Watanabe; Y Namba; M Hanaoka
Journal:  Neurosurg Rev       Date:  1984       Impact factor: 3.042

4.  Synergistic antitumor activity of cyclophosphamide and ABPP in the treatment of established and advanced tumors in murine tumor models.

Authors:  A M Eggermont; P H Sugarbaker; R L Marquet; J Jeekel
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

5.  The influence of cyclophosphamide on antitumor immunity in mice bearing late-stage tumors.

Authors:  F Culo; I Klapan; T Kolak
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

6.  The immunological mouse mutants nude (nu) and rhino (hrrh) generate cytotoxic effector cells following adoptive immunotherapy but fail to reject a transplanted tumor.

Authors:  R Evans; T M Duffy; L D Shultz
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Local administration of cytostatic drug 4-hydroperoxy-cyclophosphamide (4-HPCY) facilitates cell-mediated immune reactions.

Authors:  G H Boerrigter; R J Scheper
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

8.  Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden.

Authors:  M Awwad; R J North
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.